Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk
(MedPage Today) -- LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study.
Patients who switched from infliximab (Remicade) to an infliximab biosimilar...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news